Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POLIVY vs CLADRIBINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Polivy is an antibody-drug conjugate (ADC) composed of a CD79b-directed monoclonal antibody (polatuzumab vedotin) conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE). Upon binding to CD79b on B-cells, the ADC is internalized and MMAE is released via proteolytic cleavage, leading to cell cycle arrest and apoptosis.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
In combination with bendamustine and rituximab for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior therapies.,In combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
FDA-approved: Treatment of hairy cell leukemia.,Off-label: Chronic lymphocytic leukemia (CLL), multiple sclerosis (relapsing forms), Waldenström macroglobulinemia, cutaneous T-cell lymphoma, and as part of conditioning regimens for hematopoietic stem cell transplantation.
1.8 mg/kg intravenously every 21 days in combination with bendamustine and rituximab for up to 6 cycles.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
The terminal elimination half-life of polatuzumab vedotin is approximately 12 days (range 8–20 days) for the antibody-drug conjugate. This supports a dosing interval of every 3 weeks. The half-life may be prolonged in patients with severe hepatic impairment.
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
MMAE is primarily metabolized via CYP3A4/5. Less than 10% is metabolized by other CYP isoforms (1A2, 2C9, 2D6, 2E1, 3A4).
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate. It is also phosphorylated by deoxyguanosine kinase in mitochondria. Catabolism involves deamination by adenosine deaminase (ADA) to 2-chloroadenine, which is further metabolized.
Polivy (polatuzumab vedotin) is eliminated primarily through catabolism into small peptides and amino acids. The antibody-drug conjugate is not significantly excreted renally as intact compound; approximately <1% of the dose is excreted unchanged in urine. The majority of the drug is metabolized and eliminated via biliary/fecal routes, with approximately 80% of the total dose recovered in feces over 3 weeks, primarily as metabolites.
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
The conjugate is highly protein-bound (>97%), primarily to plasma proteins such as albumin. The free drug (unconjugated MMAE) is approximately 70–80% bound to albumin.
Approximately 20–30% bound to plasma proteins.
The volume of distribution at steady state is approximately 3.4 L (range 2.8–5.6 L), which corresponds to about 0.049 L/kg (assuming 70 kg). This small Vd indicates limited extravascular distribution, consistent with a large antibody-drug conjugate that remains primarily in the vascular space.
Approximately 4.5 L/kg (range 2.3–9.6 L/kg), indicating extensive tissue distribution.
Bioavailability is 100% for the intravenous route. No oral formulation exists; the drug is administered only as an intravenous infusion.
Oral: approximately 37–55% (first-pass metabolism); subcutaneous: approximately 100%.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease.
GFR <50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate or severe hepatic impairment (Child-Pugh B or C).
Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Safety and efficacy not established in pediatric patients.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course). No specific pediatric dose adjustments beyond weight-based dosing.
No specific dose adjustment recommended for elderly patients; monitor for increased toxicity, particularly infections and myelosuppression.
No specific dose adjustment recommended; monitor renal function and adjust accordingly.
No FDA black box warning.
WARNING: Neurotoxicity and Hematologic Toxicity. Cladribine can cause severe bone marrow suppression (neutropenia, anemia, thrombocytopenia) and neurotoxicity (including paralysis, coma, and death). Dose-dependent and more frequent in high doses.
Peripheral neuropathy: Monitor for new or worsening neuropathy; may require dose modification or discontinuation.,Infusion-related reactions: Premedicate with antihistamines and antipyretics; monitor during infusion.,Myelosuppression: Neutropenia, thrombocytopenia, and anemia; monitor blood counts regularly.,Infections: Increased risk of serious infections, including opportunistic infections.,Hepatotoxicity: Elevations of liver enzymes; monitor liver function.,Pneumonitis: Interstitial lung disease; monitor for pulmonary symptoms.,Tumor lysis syndrome: Monitor patients at risk and manage accordingly.,Embryo-fetal toxicity: Can cause fetal harm; advise effective contraception.
Myelosuppression: Monitor blood counts regularly; dose adjustment or discontinuation may be needed.,Neurotoxicity: Risk increased with high doses and in patients with renal impairment.,Nephrotoxicity: Use with caution in renal impairment; reduce dose if Cr Cl < 60 m L/min.,Hepatotoxicity: Monitor liver function tests.,Secondary malignancies: Increased risk of myelodysplasia and acute myeloid leukemia.,Infections: Increased susceptibility due to lymphopenia; consider prophylaxis.
Concomitant use with strong CYP3A4 inhibitors or inducers (avoid due to potential alteration of MMAE exposure).,Hypersensitivity to polatuzumab vedotin or any component of the formulation.
Hypersensitivity to cladribine or any component of the formulation.,Pre-existing severe bone marrow suppression (e.g., neutropenia, thrombocytopenia) unless due to underlying disease.,Pregnancy: Can cause fetal harm.,Lactation: Discontinue nursing or drug.
No specific food interactions have been reported. Maintain adequate hydration. Avoid grapefruit or grapefruit juice if also taking certain CYP3A4 substrates, but no direct interaction with POLIVY.
No significant food interactions. Avoid grapefruit juice due to potential CYP3A4 interaction (though minimal). Maintain adequate hydration to prevent tumor lysis syndrome in hematologic malignancies.
Based on its mechanism of action as an antibody-drug conjugate targeting CD79b, POLIVY (polatuzumab vedotin-piiq) is expected to cause fetal harm when administered to pregnant women. There are no adequate and well-controlled studies in pregnant women. Verifies embryolethal and teratogenic effects in animal studies. The drug should be avoided during pregnancy, and women of reproductive potential should use effective contraception during treatment and for at least 3 months after the final dose.
FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third trimesters: Risk of fetal myelosuppression, intrauterine growth restriction, and preterm labor. Cladribine crosses the placenta and may cause fetal hematopoietic suppression.
There is no information regarding the presence of polatuzumab vedotin in human milk, its effects on the breastfed infant, or its effects on milk production. Due to the potential for serious adverse reactions in nursing infants, advise women not to breastfeed during treatment with POLIVY and for at least 3 months after the final dose. M/P ratio is not known.
Contraindicated during breastfeeding. Cladribine is excreted into human milk; M/P ratio not determined. Potential for severe adverse effects in nursing infants, including myelosuppression and immunosuppression. Discontinue breastfeeding during therapy and for at least 7 days after last dose.
No specific dose adjustment recommendations are available for pregnancy due to lack of pharmacokinetic data in pregnant women. The drug is not recommended for use during pregnancy. If treatment must be administered during pregnancy, use the standard adult dose based on body weight (1.8 mg/kg actual body weight) as a 90-minute IV infusion every 21 days in combination with other agents. Monitor for toxicity and consider dose modifications for adverse events per standard guidelines.
No established dose adjustments in pregnancy. Use is contraindicated. If unavoidable, lowest effective dose and close monitoring for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure; however, risks outweigh benefits.
POLIVY (polatuzumab vedotin-piiq) is an antibody-drug conjugate targeting CD79b, used in combination with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Monitor for infusion-related reactions, peripheral neuropathy, and myelosuppression. Pre-medicate with antihistamines and antipyretics. Avoid in patients with moderate to severe hepatic impairment.
Cladribine is a purine nucleoside analog that causes lymphocyte depletion, effective in hairy cell leukemia and multiple sclerosis. Monitor for severe lymphopenia, opportunistic infections (e.g., herpes zoster, tuberculosis), and delayed myelosuppression. Do not administer live vaccines during or after treatment. Due to high bioavailability after subcutaneous administration, adjust dose for renal impairment. Hypersensitivity reactions may occur; premedicate with antihistamines if needed.
This drug is given as an intravenous infusion; you may experience allergic reactions during or after infusion.,Report any numbness, tingling, or weakness in your hands or feet immediately.,You will have regular blood tests to monitor your blood cell counts and liver function.,Use effective contraception during treatment and for at least 3 months after the last dose.,Do not receive live vaccines while on this medication.
Cladribine can significantly lower your white blood cell count, increasing infection risk. Report fever, chills, or sore throat immediately.,Avoid live vaccines (e.g., MMR, shingles) during and for at least 6 months after treatment.,You may experience fatigue, nausea, headache, or skin reactions at injection site. These are common but report severe symptoms.,Use effective contraception during treatment and for at least 6 months after the last dose. Cladribine may harm a fetus.,You will need regular blood tests to monitor your blood cell counts, liver, and kidney function.
No interactions on record
"The combination of cabazitaxel and cladribine may potentiate myelosuppression due to overlapping bone marrow toxicity profiles. Cabazitaxel, a taxane antineoplastic, inhibits microtubule disassembly, while cladribine, a purine analog, incorporates into DNA and induces apoptosis in dividing and resting lymphocytes. Concurrent use increases the risk of severe neutropenia, thrombocytopenia, and anemia, potentially leading to febrile neutropenia or bleeding complications."
"Cladribine, a purine nucleoside analog with potent immunosuppressive properties, may reduce the pharmacodynamic effects of cardiac glycosides such as acetyldigitoxin. This interaction is hypothesized to occur through cladribine-induced modulation of myocardial cellular signaling pathways that decrease sensitivity to digitalis compounds, potentially leading to reduced inotropic efficacy. Clinically, this could manifest as diminished control of heart rate in patients with atrial fibrillation or worsening heart failure symptoms, particularly in those relying on acetyldigitoxin for rate control or inotropic support."
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POLIVY vs CLADRIBINE, answered by our medical review team.
POLIVY is a Antineoplastic Agent that works by Polivy is an antibody-drug conjugate (ADC) composed of a CD79b-directed monoclonal antibody (polatuzumab vedotin) conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE). Upon binding to CD79b on B-cells, the ADC is internalized and MMAE is released via proteolytic cleavage, leading to cell cycle arrest and apoptosis.. CLADRIBINE is a Antineoplastic Agent that works by Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POLIVY and CLADRIBINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POLIVY is: 1.8 mg/kg intravenously every 21 days in combination with bendamustine and rituximab for up to 6 cycles.. The standard adult dose of CLADRIBINE is: 0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POLIVY and CLADRIBINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POLIVY is classified as Category C. Based on its mechanism of action as an antibody-drug conjugate targeting CD79b, POLIVY (polatuzumab vedotin-piiq) is expected to cause fetal harm when administered to pregnant wome. CLADRIBINE is classified as Category C. FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.